SABA monotherapy in mild asthma remained as the last example of guideline-
recommended bronchodilator therapy delivered without concomitant anti-inflammatory ICS …

The development of tolerance to the bronchodilator effects of β2-agonists used in asthma
therapy has been the subject of debate. We conducted two placebo-controlled crossover …

Inhaled long-acting β2-adrenoceptor agonists (LABAs) are highly effective bronchodilators
in the treatment of asthma and chronic obstructive pulmonary disease. There is significant …

Inhaled corticosteroids are the mainstay of asthma therapy; however, inhaled long-acting β2-
agonists (LABAs) are frequently used in the treatment of patients with asthma. LABAs are …

The development of long-acting inhaled beta agonists has resulted in a new class of asthma
medication combining the unparalleled efficacy of beta2-selective inhaled agents with the …

In moderate‐to‐severe asthma, adding an inhaled long‐acting β2‐adenoceptor agonist
(LABA) to an inhaled corticosteroid (ICS) provides better disease control than simply …

The combination of long-acting beta-agonist (LABA) bronchodilators with inhaled
corticosteroids (ICSs) has been shown to be an extremely effective treatment for asthma …

The role of the ß 2-adrenergic receptor in both the pathogenesis and treatment of asthma
has been a subject of intense speculation and investigation for 25 years. The physiological …

Inhaled β 2-adrenoceptor agonists (β 2-agonists) are the most commonly used asthma
medications in many Western countries. Minor adverse effects such as palpitations, tremor …

The mechanisms behind the long duration of bronchodilating action of the β 2-adrenoceptor
agonists formoterol and salmeterol are only partially understood. This review compares …